Navigation Links
AASLD Foundation's Liver Disease Research and Education Initiatives Bolstered by Significant Donation from Allergan
Date:2/9/2017

ALEXANDRIA, Va. and DUBLIN, Feb. 9, 2017 /PRNewswire/ -- The American Association for the Study of Liver Diseases (AASLD) Foundation, the largest private supporter of hepatology research in the United States, today announced a significant donation from Allergan to support the AASLD Foundation's research and education initiatives. With this donation, Allergan joins the AASLD Foundation's Founder's Society, the premier donor recognition circle established to honor the generosity and commitment of companies who partner with AASLD Foundation to ensure more resources for liver disease research and advanced hepatology training. AASLD Foundation's Founder's Society companies have each made commitments of $2 million or more to support AASLD Foundation's mission to invest in innovative hepatology research and in the people who study and treat liver disease.

"AASLD Foundation is proud of the impact we are making," says Bruce Bacon, MD, FAASLD, the AASLD Foundation's board of trustees Chair. "In 2016, we invested $2.63 million to fund the ideas of bright young investigators and to provide training opportunities for future hepatology leaders. However, we know there is so much more to be done, and we are grateful that Allergan recognizes that, too. This donation signifies Allergan's partnership in the fight against liver disease and its desire for a long-term investment in the discovery of innovative treatment options that promise improved patient care as well as training more professionals to care for liver disease patients. Their corporate philanthropy will help reduce the annual gap of nearly $4 million needed to fully fund meritorious research and career development awards over the next few years. This commitment will also ensure new resources are created through initiatives like the Foundation's Fundamentals of Liver Disease so more professionals are trained to care for liver disease patients."

"Allergan is focused on identifying, developing and bringing forward innovative treatments for patients with significant unmet medical needs, including non-alcoholic steatohepatitis (NASH). The Foundation's efforts in research and training are directly aligned with several of the principles of Allergan's Social Contract with Patients, making this an ideal organization for our philanthropy," says Gavin Corcoran, MD, FACP, Chief Medical Officer, Allergan. "This donation underscores Allergan's commitment to supporting research and educational initiatives that advance medical innovation and the ability to save more lives, which is possible through increased research and enhanced hepatology training opportunities."

For more information about the AASLD Foundation, visit aasldfnd.org. And, for more information about Allergan, visit Allergan.com.

Allergan NASH Programs

Allergan has demonstrated category leadership in several gastrointestinal disorders (GI) and shown continued commitment to innovate and advance science and treatments for unmet medical needs. Currently, NASH represents one of the greatest unmet medical needs and is a natural and fluid extension of Allergan's broad GI portfolio. 

Late last year, Allergan acquired cenicriviroc (CVC), evogliptin and AGN-242266 (formerly AKN-083), three differentiated, complementary programs targeting different mechanisms for the multi-factorial treatment of NASH. CVC is a first-in-class, once-daily, oral Phase 3 ready, potent immunomodulator that blocks two chemokine receptors, CCR2 and CCR5, which are involved in inflammatory and fibrogenic pathways. AGN-242266 is a potentially best-in-class preclinical farnesoid X receptor (FXR) agonist in development for the treatment of NASH, and is highly complementary to CVC and Evogliptin. Allergan is committed to advancing its overall portfolio of NASH programs, to focus on bringing forward effective treatments for this critical disease area.

About the AASLD Foundation

AASLD Foundation is a 501 (c)(3) charitable organization with a mission of investing in innovative hepatology research and in the people who study and treat liver disease. Visit aasldfnd.org to learn more about our work, or aasldfnd.org/donate to support more liver disease research and advanced hepatology training. 

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, uncertainty associated with the development of commercially successful branded pharmaceutical products; the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

Media Contacts:

Erin Meadows 703.299.9766 emeadows@aasld.org

Lisa DeFrancesco Investor Relations 862.261.7152 lisa.defrancesco@allergan.com

Mark Marmur Media Relations 862.261.7558 mark.marmur@allergan.com

Tara Schuh Public Relations 201.427.8888 tara.schuh@allergan.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aasld-foundations-liver-disease-research-and-education-initiatives-bolstered-by-significant-donation-from-allergan-300404642.html


'/>"/>
SOURCE Allergan plc
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Eiger Announces Additional LOWR HDV Program Data, Clinical and Regulatory Plans at the American Association for the Study of Liver Diseases (AASLD) Meeting
2. Benitec Biopharmas Abstract Accepted for Presentation at the AASLD Liver Meeting 2015
3. Tobira Therapeutics Highlights Presentations at the AASLDs Industry Colloquium for Novel Targets and Therapies in Liver Disease
4. Spring Bank Pharmaceuticals to Present Novel Approach to Hepatitis B Treatment at the 2015 AASLD and Industry Colloquium
5. Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting
6. Janssen Highlights its Hepatitis C Clinical Development Program in Advance of 2014 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
7. AASLD/EASL Special Conference on Hepatitis C, Sheraton New York Times Square Hotel September 12 - 13, 2014
8. Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting
9. Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting
10. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
11. Biophotonics - Global Strategic Business Report 2015 - Private Foundations Come Forth to Invest in Biophotonics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... -- New York City-based market research firm Kalorama Information notes seven ... From new products to new costs, to the threat of ... study, Potential Pipeline Disruptors . Among them ... 1.  Age-Driven Growth - True Impact Moment Arriving   ... the growing population and, to a more extreme extent, the ...
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... Administration (FDA) has agreed to schedule an End-of-Phase II ... trial of its oral insulin capsule ORMD-0801 in the ... met primary and secondary endpoints by indicating a statistically ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... 2017 , ... The Topricin Companies, formerly Topical Biomedics, is ... natural, after-burn skin care product, Topricin After Burn Cream. , Overexposure ... conditions, including cancer. In the short term, overexposure to sun, wind and ...
(Date:7/24/2017)... Beach, California (PRWEB) , ... July 24, 2017 ... ... commercialization of autologous fat (adipose) transfer systems announces the issuance of United States ... ‘324 patent) for its adipose filtration technology. The '398 and '324 patents ...
(Date:7/24/2017)... ... July 24, 2017 , ... Sharon Kleyne, host of the ... Health on VoiceAmerica sponsored by Nature’s Tears® EyeMist® recently talked on the air about ... in China. , The article by Zidor Aldama described the situation in which Chinese ...
(Date:7/24/2017)... ... July 24, 2017 , ... A Southern California-based author has released a ... and how she has overcome them. “Forbidden Memories: A Memoir,” by author Michelle V. ... she has risen above. , In “Memories,” readers get a firsthand look at what ...
(Date:7/24/2017)... Huntingdon Valley, PA (PRWEB) , ... July 24, 2017 , ... ... wind and rain storms wreak havoc across communities and often result in massive tree ... Top 3 actions homeowners can take now including tree trimming, tree cabling and hazardous ...
Breaking Medicine News(10 mins):